Login to Your Account

$61.8M+ NovaMed Acquisition Strengthens SciClone in China

By Tom Wall

Wednesday, April 20, 2011
SciClone Pharmaceuticals Inc. strengthened its hand in China with the acquisition of privately held specialty pharmaceutical company NovaMed Pharmaceuticals Inc., of Shanghai, for $61.8 million in up-front cash and stock and a potential $43 million in earn-outs for the 2011 and 2012 fiscal years.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription